---
title: The Way Forward in Therapeutic Antibody Purification
description: Join us for this webinar to learn more on novel affinity chromatography solutions and how they can help overcome challenges in the downstream process of your novel antibody therapeutic.
image: https://bpi.bioprocessintl.com/hubfs/shutterstock_459376048.jpg
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png)

# The Way Forward in Therapeutic Antibody Purification

Please join us for this free, live Ask the Expert webcast.

Just fill out the form below to register.

|  |
| --- |

## Presenter:

****![anna le bris 150x190](https://bpi.bioprocessintl.com/hs-fs/hubfs/anna%20le%20bris%20150x190.png?width=133&name=anna%20le%20bris%20150x190.png)****

**Dr. Anna Le Bris**  
Senior Application Specialist and Trainer

Thermo Fisher

 

Dr. Anna Le Bris is a Senior Application Specialist and Trainer for purification within the Bioproduction Division at Thermo Fisher Scientific.

 

Anna holds a PhD in Protein Biochemistry from the Max-Planck-Institute of Biochemistry in Munich (2007) where she focused on the production and purification of proteins. She has 20 years of experience in the chromatography field, both academic and industrial, 10 years of which have been at Thermo Fisher Scientific.

Her technical expertise includes consultancy on purification and chromatography of bioprocess molecules, ranging from protocol development/optimization to packing support. In her current role, Anna provides external trainings, seminars, consulting, and technical support in Europe, Russia, and Turkey for the POROS and CaptureSelect Chromatography product lines. Additionally, she is in charge of internal education programs for downstream processing (DSP) application aspects and soft skills training, helping the support team to collaborate with customers and support their bioprocess applications.

## About this event:

#### Date: August 19, 2021

#### Time: 11 am EDT | 8 am PDT | 5 pm CEST

#### Duration: 15 minutes

The development of therapeutic antibodies has made an enormous progression in the last decades. Antibodies have become the predominant class of biological drugs and are used to treat a variety of diseases such as cancer. Recently, neutralizing antibodies to halt infectious diseases are entering the clinical pipeline, including against Sars-Cov2.

Affinity purification platforms such as Protein A or L are well established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bispecific antibodies, fragments, and Fc-fusion proteins, challenges in the downstream process of these molecules arise. Affinity chromatography resins, specifically developed to bind antibody-subdomain regions, can provide an alternative solution in the purification process of these new formats, thus advancing the commercial production of new antibody therapeutics.

Join us for this webinar to learn more on novel affinity chromatography solutions and how they can help overcome challenges in the downstream process of your novel antibody therapeutic.

Viewers of this webinar will discover:

- How novel affinity purification solutions can improve efficiency of a downstream process.
- Affinity chromatography alternatives to Protein A and L, including purification examples of novel antibody modalities.
- How affinity chromatography could also benefit your antibody polishing process.

-  

-  

©2015 BioProcess International All Rights reserved